Treating Perinatal Mood and Anxiety Disorders
Search
AdvertisementAdvertisement
July 17, 2026/Behavioral Health/Research
Treating Perinatal Mood and Anxiety Disorders: A Call to Action
Protecting maternal health through clinician education and timely psychiatric interventions
Image content: This image is available to view online
View image online(https://assets.clevelandclinic.org/transform/cec35f90-835a-47e9-9819-35b955d788a9/mother-in-hospital-room-waiting-1407170582)
Depressed patient in labor and delivery
This editorial is reprinted without references from the Cleveland Clinic Journal of Medicine (April 2026, 93(4) 207-209 doi.org/10.3949/ccjm.93a.26002).The open-access and fully referenced original article is available at https://www.ccjm.org/content/93/4/207
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services.Policy
By Lulu Zhao, MD
When Cohen et al published their 2006 landmark study on the relapse of depression during pregnancy, they stated, “There has been a common belief that characteristic hormonal changes associated with pregnancy are inherently ‘protective’ with respect to … depression … and that discontinuation of psychiatric medications should be almost uniformly pursued given concerns regarding prenatal exposure to these agents.”
We now know that pregnancy confers no such protection. One in 5 individuals giving birth in the United States experiences a mood disorder during the perinatal period (during pregnancy or up to 1 year postpartum). Anxiety is the most common (20.7%), followed by depression (12.1%). Other conditions such as mania, postpartum psychosis, and post-traumatic stress disorder are less common but can create an outsized effect on the health and life trajectories of those affected
Various factors drive the high incidence of perinatal mood and anxiety disorders. During pregnancy, a massive influx of estrogen and progesterone —both sex hormones and neuroactive steroids — promote neuroplasticity. Accordingly, the brain undergoes significant neuroanatomic remodeling during the perinatal period. [These shifts] invite parents to imagine new ways of relating to the world around them. For individuals with biologic and psychosocial vulnerabilities, however, these new thought patterns may be maladaptive.
Consequences of untreated illness
Untreated perinatal mood and anxiety disorders create an environment of psychosocial toxicity that devolves into longitudinal adversity. Studies show that depressed parents are less able to engage in productive relationships, including with their newborn children
Advertisement
Maternal depression in the postpartum year is also strongly associated with an increased unemployment risk for up to 15 years after childbirth, with an estimated societal cost of nearly $31,800 per affected mother-child dyad over the first 6 years. Meanwhile, the leading cause of death for mothers in the first year postpartum is untreated mental health disorders, outranking serious conditions like hemorrhage and hypertensive disease
Currently, perinatal mood and anxiety disorders remain untreated in 3 of 4 affected individuals giving birth, and the discrepancy between needing care and receiving care is highest in our most vulnerable populations: the marginalized, the socioeconomically disadvantaged, the isolated and the inadequately insured
Prioritizing mental healthcare
Where does that leave our patients who struggle with their mental health while juggling the responsibilities of a growing family? Many will rely on the knowledge and judgment of non–mental health specialists (e.g., obstetricians and primary care clinicians). It is noteworthy that more than half of women discontinue antidepressant medications during pregnancy. Yet, 53% of these women will end up back on antidepressants in the postpartum period, as the risk of symptom recurrence is 50% to 70% even in those who were euthymic at the time of discontinuation.
Treatment decisions during pregnancy should therefore be framed as a risk-risk discussion. Lack of treatment is not neutral — untreated perinatal mood and anxiety disorders themselves are associated with adverse obstetrical and neurodevelopmental outcomes. Decades of quality, peer-reviewed research have demonstrated the favorable safety profile of selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed class of medications for depression and anxiety
Advertisement
Women with depression who are treated with SSRIs during pregnancy exhibit no clinically significant increased risk of miscarriage, fetal growth restriction, preterm birth, cesarean birth, or adverse neurodevelopmental outcomes compared with those with untreated depression. SSRIs are also widely considered compatible with breastfeeding because low amounts of these medications pass into breast milk
Meanwhile, risks that do exist should be put into proper context. The baseline risk of birth defects in all pregnancies is about 3%. Exposure to an SSRI during pregnancy, including paroxetine, increases the risk of birth defects by less than 1%
Traditional vs. novel agents
Timing is another consideration that significantly impacts a patient’s quality of life. Traditional antidepressants like SSRIs must be used for 4 to 6 weeks at a therapeutic dose to yield significant clinical benefit. Today, postpartum patients have access to a new medication class that mimics the action of progesterone metabolites at the gamma-aminobutyric acid receptor
The rapid onset of these medications can produce reductions in depression scores within days. While more research is needed on which populations benefit most from traditional antidepressants vs novel ones, patients and clinicians alike now have more options to treat these serious mental health conditions
It is imperative that obstetricians and primary care clinicians achieve basic competency in managing psychiatric disorders during the perinatal period. If we hope to see improved mental wellness for our mothers, families, and communities, we must all play an active role
Advertisement
Advertisement
Related Articles
May 29, 2026/Behavioral Health/Case Study
Case Study: When Psychiatric Symptoms Blur the Lines in Multiple Sclerosis Care
https://consultqd.clevelandclinic.org/case-study-when-psychiatric-symptoms-blur-the-lines-in-multiple-sclerosis-care
Complex presentation underscores the overlap between MS-related complaints and bipolar-spectrum illness
May 1, 2026/Behavioral Health/Podcasts
Women’s Behavioral Health (Podcast)
https://consultqd.clevelandclinic.org/womens-behavioral-health-podcast
How hormonal transitions shape women’s mental health across the lifespan
March 16, 2026/Behavioral Health/Podcasts
ADHD Across the Lifespan: Managing a Common and Often Misunderstood Disorder (Podcast)
https://consultqd.clevelandclinic.org/adhd-across-the-lifespan-managing-a-common-and-often-misunderstood-disorder-podcast
Current diagnostic and treatment strategies can help improve focus, productivity and quality of life
February 27, 2026/Behavioral Health/Research
When More Isn’t Better: ChatGPT’s Readability Gap in Opioid Use Disorder Education
https://consultqd.clevelandclinic.org/when-more-isnt-better-chatgpts-readability-gap-in-opioid-use-disorder-education
New study highlights the need for plain-language prompting and human oversight in addiction care communication
February 24, 2026/Behavioral Health/Research
When Depression Isn’t Depression: New Study Highlights Diagnostic Gaps in Hospital Care
https://consultqd.clevelandclinic.org/when-depression-isnt-depression-new-study-highlights-diagnostic-gaps-in-hospital-care
What hospital clinicians get right — and wrong — when diagnosing depression and delirium
December 11, 2025/Behavioral Health/Case Study
Beyond the Classic Triad: an Updated Approach to Wernicke’s Encephalopathy
https://consultqd.clevelandclinic.org/beyond-the-classic-triad-an-updated-approach-to-wernickes-encephalopathy
Swift, aggressive thiamin therapy may be key to preventing long-term neurological injury
November 11, 2025/Behavioral Health/Research
Hypertensive Crisis Linked to Psilocybin Mushroom Use in Patient Taking MAOI and Amphetamine
https://consultqd.clevelandclinic.org/hypertensive-crisis-linked-to-psilocybin-mushroom-use-in-patient-taking-maoi-and-amphetamine
Case underscores potential dangers of combining psychedelics with tranylcypromine and stimulant medications
October 7, 2025/Behavioral Health/Research
Unraveling the Gut-Alcohol Connection After Bariatric Surgery
https://consultqd.clevelandclinic.org/unraveling-the-gut-alcohol-connection-after-bariatric-surgery
Researchers explore how changes in the gut microbiome influence the brain’s reward response to alcohol
Ad
Rendered: Fri Jul 17 2026 05:49:03 GMT+0000 (Coordinated Universal Time)
